Answers are grounded in this paper and cite their sources.
Mogamulizumab is a monoclonal antibody targeting CC-chemokine receptor-4 that is approved as a second-line therapy for mycosis fungoides and Sézary syndrome. The most common adverse events include infusion-related reactions and mogamulizumab-associated rash. Conversely, solid organ involvement in immune-related adverse events has been limited to sporadic reports. Regarding mogamulizumab, hepatobiliary complications appear to occur predominantly alongside the reactivation of viral hepatitis. As management differs substantially from that of infectious hepatitis and immune-mediated adverse events involving solid organs are potentially life-threatening, their early recognition and attribution to mogamulizumab therapy are of high clinical importance. Treatment depends on severity, and interruption of therapy may be required. We report five cases of non-infectious hepatobiliary adverse events during mogamulizumab treatment and summarize the current state of the literature. The aim is to emphasize the importance of early recognition of immune-mediated toxicities affecting solid organs during mogamulizumab therapy in the management of patients with cutaneous lymphomas.
No takes yet. Share an insight, caveat, or question.
Hansen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: